What is Wuhan YZY Biopharma Co Earnings Yield (Joel Greenblatt) %?
Wuhan YZY Biopharma Co's Enterprise Value for the quarter that ended in Dec. 2023 was HK$1,608.69 Mil.
Wuhan YZY Biopharma Co does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2023. Therefore, GuruFocus does not calculate Wuhan YZY Biopharma Co's Earnings Yield (Joel Greenblatt) at this moment.
The historical rank and industry rank for Wuhan YZY Biopharma Co's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
HKSE:02496'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -15.6 Med: 0 Max: 0
Current: -15.6
HKSE:02496's Earnings Yield (Joel Greenblatt) % is ranked better than 50.04% of 1413
companies
in the Biotechnology industry
Industry Median: -15.67
vs HKSE:02496: -15.60
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Wuhan YZY Biopharma Co's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Wuhan YZY Biopharma Co Earnings Yield (Joel Greenblatt) % Historical Data
The historical data trend for Wuhan YZY Biopharma Co's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Wuhan YZY Biopharma Co Earnings Yield (Joel Greenblatt) % Chart
Wuhan YZY Biopharma Co Annual Data
Trend
Dec21
Dec22
Dec23
Earnings Yield (Joel Greenblatt) %
-
-
-12.87
Wuhan YZY Biopharma Co Semi-Annual Data
Dec21
Dec22
Dec23
Earnings Yield (Joel Greenblatt) %
-
-
-12.87
Competitive Comparison of Wuhan YZY Biopharma Co's Earnings Yield (Joel Greenblatt) %
For the Biotechnology subindustry, Wuhan YZY Biopharma Co's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wuhan YZY Biopharma Co's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Wuhan YZY Biopharma Co's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Wuhan YZY Biopharma Co's Earnings Yield (Joel Greenblatt) % falls into.
Wuhan YZY Biopharma Co Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Wuhan YZY Biopharma Cos Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as
Wuhan YZY Biopharma Co (HKSE:02496) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Wuhan YZY Biopharma Co Earnings Yield (Joel Greenblatt) % Related Terms
Thank you for viewing the detailed overview of Wuhan YZY Biopharma Co's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.
Wuhan YZY Biopharma Co (HKSE:02496) Business Description
Wuhan YZY Biopharma Co Ltd is a biotechnology company specifically involved in developing bispecific antibody based therapies to treat cancer or cancer-associated complications, cancer and age-related ophthalmologic diseases to address medical demands in oncology and aging-related ophthalmologic disease areas, The Company has been operating in one reportable segment, being the discovering, developing and commercializing new class of innovative medicines in respect to anti-tumor bispecific antibody.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02496 has been successfully added to your